Vorasidenib Products | Cleanchem - Vorasidenib is an investigational drug that inhibits mutant forms of isocitrate dehydrogenase (IDH1 and IDH2), enzymes commonly mutated in certain types of brain tumors and leukemias. By targeting these mutations, vorasidenib helps reduce the production of the oncometabolite 2-HG, which contributes to cancer cell growth. It is being developed for the treatment of low-grade gliomas and other IDH-mutated cancers. Early studies have shown promising activity in slowing tumor progression.

Cat. No: CL-VOCL-01

CAS No: NA

Mol. F: C63H111N11O12

Mol. Wt: 1214.6

Inv. Status: Custom Synthesis

Cat. No: CL-VORA-02

CAS No: 1644545-52-7

Mol. F: C14H13ClF6N6

Mol. Wt: 414.7

Inv. Status: Custom Synthesis

Cat. No: CL-VORA-03

CAS No: 1644545-50-5

Mol. F: C14H10ClF9N6

Mol. Wt: 468.7

Inv. Status: Custom Synthesis

Cat. No: CL-VORA-04

CAS No: 1644545-49-2

Mol. F: C16H17ClF6N6

Mol. Wt: 442.8

Inv. Status: Custom Synthesis

Cat. No: CL-VORA-05

CAS No: 1644545-51-6

Mol. F: C20H22F6N6

Mol. Wt: 460.4

Inv. Status: Custom Synthesis

Cat. No: CL-VORA-06

CAS No: 1644385-74-9

Mol. F: C19H24ClN5

Mol. Wt: 357.9

Inv. Status: Custom Synthesis

Cat. No: CL-VORA-07

CAS No: 1644385-38-5

Mol. F: C16H18F3N7O

Mol. Wt: 381.4

Inv. Status: Custom Synthesis